(Q33402978)

English

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03.

scientific article

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

0 references

1 reference

based on heuristic

inferred from title

21

object named as

Patrick Y Wen

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

1

object named as

Eudocia Q Lee

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Timothy F. Cloughesy

6

object named as

Timothy F Cloughesy

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

8

object named as

Jan Drappatz

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Andrew B Lassman

13

object named as

Andrew B Lassman

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Susan Soon Mee Chang

7

object named as

Susan M Chang

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vinay K Puduvalli

2

object named as

Vinay K Puduvalli

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

4

object named as

John G Kuhn

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Frank Lieberman

12

object named as

Frank S Lieberman

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Michael D Prados

20

object named as

Michael D Prados

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

author name string

Joel M Reid

3

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Kathleen R Lamborn

5

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

W K Alfred Yung

9

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Mark R Gilbert

10

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

H Ian Robins

11

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Renee M McGovern

14

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Jihong Xu

15

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Serena Desideri

16

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Xiabu Ye

17

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Matthew M Ames

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Igor Espinoza-Delgado

19

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

language of work or name

0 references

publication date

24 August 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

18

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

21

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

6032-6039

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Vorinostat modulates cell cycle regulatory proteins in glioma cells and human glioma slice cultures.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Histone deacetylase inhibitors in cancer therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Vorinostat in solid and hematologic malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Continuous intracranial administration of suberoylanilide hydroxamic acid (SAHA) inhibits tumor growth in an orthotopic glioma model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Suberoylanilide hydroxamic acid (SAHA) has potent anti-glioma properties in vitro, ex vivo and in vivo

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

A phase I trial of 1,3-bis(2-chloroethyl)-1-nitrosourea plus temozolomide: a North American Brain Tumor Consortium study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Phase I trial of temozolomide (NSC 362856) in patients with advanced cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

21 June 2018

Suberoylanilide hydroxamic acid limits migration and invasion of glioma cells in two and three dimensional culture

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3947570

31 October 2018

A liquid chromatography-electrospray ionization tandem mass spectrometric assay for quantitation of the histone deacetylase inhibitor, vorinostat (suberoylanilide hydroxamicacid, SAHA), and its metabolites in human serum

1 reference

https://pubmed.ncbi.nlm.nih.gov/22923449

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-12-1841

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 July 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q33402978&oldid=1857584111"